Virtuoso Therapeutics is focused on developing novel bispecific antibodies aimed at treating complex diseases, particularly cancer. Their approach to antibody engineering is distinct, leveraging unique insights and advanced capabilities to create bispecific antibodies with superior therapeutic profiles. The company is dedicated to addressing specific challenges associated with existing therapies, striving to enhance their effectiveness, selectivity, and safety. This commitment is reflected in their robust pipeline, which includes several promising bispecific antibody programs currently in various stages of development, from pre-clinical to clinical trials.

The pipeline features innovative bispecific antibodies targeting key proteins such as CD38 and CD47, which are implicated in hematological malignancies and solid tumors. By focusing on these targets, Virtuoso Therapeutics aims to overcome significant hurdles faced by current treatment options. Their team, composed of experts from around the globe, is well-positioned to drive the advancement of these novel therapies, ultimately seeking to improve patient outcomes and provide more effective treatment alternatives in the oncology landscape.

United States

Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibody therapies. Our team’s expertise and insights could address some of the fundamental challenges of these modalities, such as efficacy and therapeutic window. By applying Virtuoso’s technology and know-how, we believe our bispecific programs are highly differentiated and have the potential to achieve a unique product profile.

Virtuoso leadership has extensive experience and networks across both the US and China. Our unique US-China hybrid model enables capital-efficient virtual R&D operations, as well as access to world-class science and talent from China and the West.

Virtuoso Therapeutics

Company Details